The company’s shares rose as much as 8% at the start of regular trading in New York on Wednesday.
Management said medical costs were in line with expectations — which hasn’t been the case for many of the company’s rivals lately — and that it benefited from growth in its Medicare Advantage and pharmacy businesses.
The company raised its full-year adjusted earnings guidance to around $17 per share, up from ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.